Duchenne muscular dystrophy: Canadian paediatric neuromuscular physicians survey

Canadian Journal of Neurological Sciences

Volumn 37, Issue 2, 2010, Pages 195-205

  McMillan, Hugh J ^a   Campbell, Craig ^b   Mah, Jean K ^c  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; CORTICOSTEROID; CREATINE; DEFLAZACORT; INFLUENZA VACCINE; PAMIDRONIC ACID; PNEUMOCOCCUS VACCINE; PREDNISONE; PROTEIN; SALBUTAMOL; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; CALCIUM INTAKE; CANADA; CHILD NUTRITION; CHILDHOOD DISEASE; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DIETITIAN; DISEASE SURVEILLANCE; DUAL ENERGY X RAY ABSORPTIOMETRY; DUCHENNE MUSCULAR DYSTROPHY; ELECTROCARDIOGRAM; FOLLOW UP; HEART DISEASE; HUMAN; IMMOBILIZATION; IMMUNIZATION; LUNG FUNCTION TEST; MEDICAL SPECIALIST; MOTOR DYSFUNCTION; OCCUPATIONAL THERAPY; ORTHOPEDIC SURGERY; PALLIATIVE THERAPY; PATIENT CARE; PATIENT REFERRAL; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; SLEEP; SPINE RADIOGRAPHY; SPLINT; VACCINATION; VITAMIN SUPPLEMENTATION;

EID: 76649104350     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100009926     Document Type: Article

References (63)

1. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989;320(24):1592-1597
2. Griggs RC, Moxley RT, 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol. 1991;48(4):383-388
3. Fenichel GM, Mendell JR, Moxley RT, 3rd, Griggs RC, Brooke MH, Miller JP, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol. 1991;48(6):575-579
4. Mesa LE, Dubrovsky AL, Corderi J, Marco P, Flores D. Steroids in Duchenne muscular dystrophy--deflazacort trial. Neuromuscul Disord. 1991;1(4):261-266
5. Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001;138(1):45-50.
6. Schara U, Mortier, Mortier W. Long-term steroid therapy in Duchenne muscular dystrophy-positive results versus side effects. J Clin Neuromuscul Dis. 2001;2(4):179-183
7. King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007;68(19):1607-1613
8. DeSilva S, Drachman DB, Mellits D, Kuncl RW. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch Neurol. 1987;44(8):818-822
9. Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve. 1994;17(4):386-391
10. Silversides CK, Webb GD, Harris VA, Biggar DW. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol. 2003;91(6): 769-772
11. Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, Cripe LH. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol. 2005;26(6):768-771
12. Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord. 2008;18(5):365-370
13. Alman BA, Raza SN, Biggar WD. Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. J Bone Joint Surg Am. 2004;86-A(3):519-524
14. Kinali M, Main M, Eliahoo J, Messina S, Knight RK, Lehovsky J, et al. Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2007;11 (3):160-166
15. Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000;23(9):1344-1347
16. Moxley RT, 3rd, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005;64(1):13-20.
17. American Thoracic Society. Respiratory care of the patient with Duchenne muscular dystrophy. Am J Crit Care Med. 2004;170: 456-465
18. American Academy of Pediatrics. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics. 2005;166(6):1569-1573
19. TREAT-NMD.eu [homepage on the Internet]. United Kingdom. [cited 2009 Aug 17]. Available from: http://www.treatnmd. eu/userfiles/file/general/TREAT-NMD- DMD- interim-recommendations.pdf
20. Bushby K BJ, Bullock R, Eagle M, Gibson M, Quinby J. The Multidisciplinary management of Duchenne muscular dystrophy. Curr Pediatr. 2005;15:292-300.
21. Muntoni F, Bushby K, van Ommen G. 128th ENMC International workshop on 'preclinical optimization and phase I/II clinical trials using antisense oligonucleotides in Duchenne Muscular Dystrophy' 22-24 October 2004, Naarden, The Netherlands. Neuromuscul Disord. 2005;15(6):450-457
22. Griggs RC, Moxley RT, 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology. 1993;43(3 Pt 1):520-527
23. Backman E, Henriksson KG. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 1995;5(3):233-241
24. Rahman MM, Hannan MA, Mondol BA, Bhoumick NB, Haque A. Prednisolone in Duchenne muscular dystrophy. Bangladesh Med Res Counc Bull. 2001;27(1):38-42.
25. Beenakker EA, Fock JM, Van Tol MJ, Maurits NM, Koopman HM, Brouwer OF, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol. 2005;62(1):128-132
26. Reitter B. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain Dev 1995;17 Suppl: 39-43.
27. Reitter B. Motor performance of DMD boys treated with prednisone or deflazacort: interim results of a double-blind study [abstract]. Dev Med Child Neurol. 1995;37 Suppl 72:107.
28. Campbell C, Jacob P. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review. BMC Neurol. 2003;3:7.
29. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2008(1):CD003725.
30. Merlini L, Cicognani A, Malaspina E, Gennari M, Gnudi S, Talim B, et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve. 2003;27(2):222-227
31. Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul Disord. 2002;12 Suppl 1:S169-74.
32. Bachrach LK. Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. Neuromuscul Disord. 2005;15 (1):86-87
33. Biggar WD, Bachrach LK, Henderson RC, Kalkwarf H, Plotkin H, Wong BL. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord. 2005;15(1):80-85
34. Tarnopolsky M, Mahoney D, Thompson T, Naylor H, Doherty TJ. Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1. Muscle Nerve. 2004;29(1): 51-58
35. Fowler EG, Graves MC, Wetzel GT, Spencer MJ. Pilot trial of albuterol in Duchenne and Becker muscular dystrophy. Neurology. 2004;62(6):1006-1008
36. Skura CL, Fowler EG, Wetzel GT, Graves M, Spencer MJ. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology. 2008;70 (2):137-143
37. Sharma KR, Mynhier MA, Miller RG. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology. 1993;43(3 Pt 1):527-532
38. Fenichel GM, Griggs RC, Kissel J, Kramer TI, Mendell JR, Moxley RT, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology. 2001;56(8):1075-1079
39. Stern LM, Fewings JD, Bretag AH, Ballard FJ, Tomas FM, Cooper DM, et al. The progression of Duchenne muscular dystrophy: clinical trial of allopurinol therapy. Neurology. 1981;31(4): 422-426
40. Mok E, Letellier G, Cuisset JM, Denjean A, Gottrand F, Alberti C, et al. Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial. PLoS One. 2009;4(5):e5448.
41. Gamstorp I, Gustavson KH, Hellstrom O, Nordgren B. A trial of selenium and vitamin E in boys with muscular dystrophy. J Child Neurol. 1986;1(3):211-214
42. Smith AD, Koreska J, Moseley CF. Progression of scoliosis in Duchenne muscular dystrophy. J Bone Joint Surg Am. 1989;71 (7):1066-1074
43. Miller F, Moseley CF, Koreska J. Spinal fusion in Duchenne muscular dystrophy. Dev Med Child Neurol. 1992;34(9):775-786
44. Kurz LT, Mubarak SJ, Schultz P, Park SM, Leach J. Correlation of scoliosis and pulmonary function in Duchenne muscular dystrophy. J Pediatr Orthop. 1983;3(3):347-353
45. Galasko CS, Delaney C, Morris P. Spinal stabilisation in Duchenne muscular dystrophy. J Bone Joint Surg Br. 1992;74(2):210-214
46. Miller RG, Chalmers AC, Dao H, Filler-Katz A, Holman D, Bost F. The effect of spine fusion on respiratory function in Duchenne muscular dystrophy. Neurology. 1991;41(1):38-40.
47. Lankester BJA WM, Gargan MF. Duchenne muscular dystrophy. Curr Orthopaed. 2007;21:298-300.
48. Shapiro F, Sethna N, Colan S,Wohl ME, Specht L. Spinal fusion in Duchenne muscular dystrophy: a multidisciplinary approach. Muscle Nerve. 1992;15(5):604-614
49. Marsh A, Edge G, Lehovsky J. Spinal fusion in patients with Duchenne's muscular dystrophy and a low forced vital capacity. Eur Spine J. 2003;12(5):507-512
50. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord. 2003;13(2):166-172
51. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12(10): 926-929
52. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 1990;26(3):271-277
53. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol. 2005;45(6):855-857
54. Ramaciotti C, Heistein LC, Coursey M, Lemler MS, Eapen RS, Iannaccone ST, et al. Left ventricular function and response to enalapril in patients with Duchenne muscular dystrophy during the second decade of life. Am J Cardiol. 2006;98(6):825-827
55. Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am Heart J. 1999;137(5):895-902.
56. Ogata H, Ishikawa Y, Ishikawa Y, Minami R. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol. 2009;53(1):72-78
57. Garg R, Yusuf S. Overview of randomized trials of angiotensinconverting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450-1456
58. Gross R, Johnston K. Levels of evidence: taking neurology to the next level. Neurology. 2009;72:8-10.
59. Reitter B. 75th European neuromuscular centre international workshop: 2nd workshop on the treatment of muscular dystrophy, 10-12 December, 1999, Naarden, the Netherlands. Neuromusc Disord. 2000;10:313-320
60. Corrado G, Lissoni A, Beretta S, Terenghi L, Tadeo G, Foglia- Manzillo G, et al. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am J Cardiol. 2002;89(7):838-841
61. Mirabella M, Servidei S, Manfredi G, Ricci E, Frustaci A, Bertini E, et al. Cardiomyopathy may be the only clinical manifestation in female carriers of Duchenne muscular dystrophy. Neurology. 1993;43(11):2342-2345
62. Hoogerwaard EM, van der Wouw PA, Wilde AA, Bakker E, Ippel PF, Oosterwijk JC, et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 1999;9(5):347-351
63. Willig TN, Bach JR, Venance V, Navarro J. Nutritional rehabilitation in neuromuscular disorders. Semin Neurol. 1995; 15(1):18-23.